/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

87 Comunicados de prensa

Ver todos los comunicados de prensa

09/03/2026

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Sanidad

Farmacéutica

Salud

Oncología

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

20/02/2026

Mercado laboral

Oncología

Salud

Sanidad

Ciencia

Farmacéutica

Biotecnología

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

Fuente

Editor

1.00

0

19/02/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

04/02/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Fuente

Editor

1.00

0

03/02/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Fuente

Editor

1.00

0

22/01/2026

Oncología

Salud

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe

Fuente

Editor

1.00

0

19/01/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fuente

Editor

1.00

0

13/01/2026

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Industria

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Fuente

Editor

1.00

0

07/01/2026

Oncología

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Mercado laboral

Industria

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

Fuente

Editor

1.00

0

22/12/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0